RT Journal Article
SR Electronic
T1 Efficacy of a spatial repellent for control of malaria in Indonesia: a cluster-randomized controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19003426
DO 10.1101/19003426
A1 Din Syafruddin
A1 Puji BS Asih
A1 Ismail Ekoprayitno Rozi
A1 Dendi Hadi Permana
A1 Anggi Puspa Nur Hidayati
A1 Lepa Syahrani
A1 Siti Zubaidah
A1 Dian Sidik
A1 Michael J. Bangs
A1 Claus Bøgh
A1 Fang Liu
A1 Evercita C. Eugenio
A1 Jared Hendrickson
A1 Timothy Burton
A1 J. Kevin Baird
A1 Frank Collins
A1 John P. Grieco
A1 Neil F. Lobo
A1 Nicole L. Achee
YR 2020
UL http://medrxiv.org/content/early/2020/03/29/19003426.abstract
AB A cluster randomized, double-blinded, placebo-controlled trial was conducted to estimate protective efficacy of a spatial repellent against malaria infection at Sumba, Indonesia. Following radical cure in 1,341 children aged ≥ 6 months - ≤5 years in 24 clusters, households were given transfluthrin or placebo passive emanators (devices designed to release vaporized chemical). Monthly blood screening and biweekly human-landing mosquito catches were performed during 10-months baseline (June 2015 to March 2016) and a 24-month intervention period (April 2016 to April 2018). Screening detected 164 first-time infections and an accumulative total of 459 infections in 667 subjects in placebo-control households; and 134 first-time and 253 accumulative total infections among 665 subjects in active intervention households. The 24-cluster protective effect of 27.7% and 31.3%, for time to first-event and overall (total new) infections, respectively, was not statistically significant. Purportedly, this was due in part to zero to low incidence in some clusters, undermining the ability to detect a protective effect. Subgroup analysis of 19 clusters where at least one infection occurred during baseline showed 33.3% (p-value = 0.083) and 40.9% (p-value = 0.0236, statistically significant at the 1-sided 5% significance level) protective effect to first-infection and overall infections, respectively. Among 12 moderate-to high-risk clusters, a statistically significant decrease on infection by intervention was detected (60% protective efficacy). Primary entomological analysis of impact was inconclusive. While this study suggests spatial repellents prevent malaria, additional evidence is required to demonstrate the product class provides an operationally feasible and effective means of reducing malaria transmission.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02294188Funding StatementThis study was funded by a substantial award from the Bill & Melinda Gates Foundation (BMGF) to the University of Notre Dame (Grant# OPP1081737). We express our gratitude to the Foundation for their long-term generosity and support of spatial repellent product evaluation and development, especially Kate Aultman, Dan Strickman and Alan Magill. We are also deeply grateful to SC Johnson for its financial support. The company provided integral industry and product expertise including the development, manufacturing, delivery and shipment of the intervention (active and placebo) used in the study. Additionally, SC Johnson provided expertise in ensuring intervention quality, storage, application and disposal assurances throughout the trial.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.YesI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesAnalytical datasets available upon request to corresponding author.